Manometrically-guided endoscopic injection of botulinum toxin for esophageal achalasia: A pilot trial

2000 ◽  
Vol 38 (11) ◽  
pp. 899-903 ◽  
Author(s):  
T Wehrmann ◽  
Th Schmitt ◽  
C F Dietrich ◽  
W F Caspary ◽  
H Seifert
Endoscopy ◽  
1999 ◽  
Vol 31 (5) ◽  
pp. 352-358 ◽  
Author(s):  
T. Wehrmann ◽  
H. Kokabpick ◽  
V. Jacobi ◽  
H. Seifert ◽  
B. Lembcke ◽  
...  

Endoscopy ◽  
1998 ◽  
Vol 30 (08) ◽  
pp. 702-707 ◽  
Author(s):  
T. Wehrmann ◽  
H. Seifert ◽  
M. Seipp ◽  
B. Lembcke ◽  
W. F. Caspary

1998 ◽  
Vol 114 ◽  
pp. A713 ◽  
Author(s):  
V. Annese ◽  
G. Bassotti ◽  
G. Coccia ◽  
M. Dinelli ◽  
V. D'Onofrio ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e036815
Author(s):  
Ulla Klaiber ◽  
Peter Sauer ◽  
Eike Martin ◽  
Thomas Bruckner ◽  
Steffen Luntz ◽  
...  

IntroductionPostoperative pancreatic fistula (POPF) is still the most frequently occurring and clinically relevant complication after distal pancreatectomy (DP). Preoperative endoscopic injection of botulinum toxin (BTX) into the sphincter of Oddi represents an innovative approach to prevent POPF. The aim of this project (PREBOTPilot) is to generate the first randomised controlled trial data on the safety, feasibility and efficacy of preoperative endoscopic BTX injection into the sphincter of Oddi to prevent clinically relevant POPF following DP.Methods and analysisPREBOTPilot is an investigator-initiated, single-centre, randomised, controlled, open-label, phase II clinical trial with two parallel study groups and an exploratory study design. 60 patients scheduled for DP will be randomised to intervention and control group. In the intervention group, patients will undergo preoperative endoscopic injection of BTX into the sphincter of Oddi, whereas in the control group no preoperative endoscopy will be performed. The combined primary endpoint is the occurrence of clinically relevant POPF and/or death within 30 days after DP. The secondary endpoints comprise further postoperative outcome parameters and quality of life up to 3 months after DP as well as safety and feasibility of the procedure. Statistical analysis is based on the modified intention-to-treat population, excluding patients without status post DP. For safety analysis, rates of adverse events (AEs) and serious AEs will be calculated with 95% CIs for group comparisons.Ethics, funding and disseminationPREBOTPilot has been approved by the German Federal Institute for Drugs and Medical Devices (reference number 4043654) and the Ethics Committee of Heidelberg University (reference number AFmo-523/2019). This trial is supported by the German Federal Ministry of Education and Research (BMBF). The results of the trial will be presented at national and international conferences and published in a peer-reviewed journal.Trial registration numberDRKS00020401.


2011 ◽  
Vol 100 (4) ◽  
pp. 256-263 ◽  
Author(s):  
J. M. Guys ◽  
G. Hery ◽  
M. Haddad ◽  
C. Borrionne

Diagnosis of neurogenic bladder is straightforward in children with myelomeningocele. However, recognition is more difficult in patients with occult dysraphism or central nervous system disorders since clinico-anatomical correlations are poor. Careful clinical examination and urodynamic exploration are mandatory for diagnosis and follow-up. Even if urinary leak is the first symptom, the main goal of the pediatric surgeon must be to preserve the upper urinary tract. The ideal protection strategy consists of ensuring that micturition is voluntary and complete and that the bladder capacity is sufficient with adequate compliance and sphincter outlet resistances. Balancing these functions requires a combination of medical and surgical treatment. A variety of techniques can be used depending on gender and age of the patient and social environment. In most cases, intermittent bladder catheterization is necessary to obtain complete evacuation of the bladder. Bladder capacity can be increased by anticholinergic drugs, injection of botulinum toxin into the bladder, and augmentation cystoplasty. Augmentation of bladder outlet resistances requires endoscopic injection of bulking agents, surgical bladder neck reconstruction and urethral lengthening, bladder neck suspension, and artificial urinary sphincter. In difficult cases, continent cystostomy with closure of the bladder neck can achieve definitive continence. At the beginning endoscopic treatment combining anti reflux procedure, injection of the bladder neck and botulinum toxin can be considered as a “total endoscopic management” and should be our first line. Other techniques are under evaluation. Sacral neuromodulation has given promising results. Artificial tissue engineering will probably be used in the next future. Management of neurogenic bladder is not limited to urological considerations. Orthopedic, digestive, and sexual problems must also be taken into account in order to obtain an “acceptable quality of life”.


2004 ◽  
Vol 46 (6) ◽  
pp. 784-791 ◽  
Author(s):  
A. Haferkamp ◽  
B. Schurch ◽  
A. Reitz ◽  
U. Krengel ◽  
J. Grosse ◽  
...  

1998 ◽  
Vol 114 ◽  
pp. A240 ◽  
Author(s):  
JC Nebendahl ◽  
B Brand ◽  
T von Schrenck ◽  
U Matsui ◽  
F Thonke ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document